Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
63.10
+7.10 (12.68%)
At close: Feb 11, 2026

TPEX:7871 Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023
Period Ending
Jun '25 Dec '24 Dec '23
1.030.825.7
Revenue Growth (YoY)
--96.88%-
Cost of Revenue
0.790.642.21
Gross Profit
0.230.1723.48
Selling, General & Admin
48.8652.3541.42
Research & Development
174.42164.63103.01
Operating Expenses
223.29216.97144.43
Operating Income
-223.05-216.81-120.95
Interest Expense
-1.14-1.31-0.61
Interest & Investment Income
4.867.450.53
Earnings From Equity Investments
-0.31-0.31-
Currency Exchange Gain (Loss)
-4.542.411.92
Other Non Operating Income (Expenses)
-1,140-231.39391.07
EBT Excluding Unusual Items
-1,364-439.95271.95
Gain (Loss) on Sale of Assets
0.020.02-
Other Unusual Items
--0.39-
Pretax Income
-1,364-440.32271.95
Income Tax Expense
--3.74
Net Income
-1,364-440.32268.21
Net Income to Common
-1,364-440.32268.21
Shares Outstanding (Basic)
242222
Shares Outstanding (Diluted)
242280
Shares Change (YoY)
--72.30%-
EPS (Basic)
-57.44-19.9012.27
EPS (Diluted)
-57.45-19.903.36
Free Cash Flow
-205.93-249.67-105.55
Free Cash Flow Per Share
-8.67-11.28-1.32
Gross Margin
22.81%20.67%91.38%
Operating Margin
-21739.86%-26999.63%-470.70%
Profit Margin
-132970.96%-54833.75%1043.79%
Free Cash Flow Margin
-20070.76%-31091.78%-410.76%
EBITDA
-218.83-213.69-117.9
D&A For EBITDA
4.223.123.05
EBIT
-223.05-216.81-120.95
Effective Tax Rate
--1.38%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.